Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
In the genesis and maintenance of PH associated with liver cirrhosis are two mechanisms that
act synergistically. The first is an increase in hepatic vascular resistance, due in part to
the disruption of liver structure inherent cirrhosis, and increased hepatic vascular tone is
caused by the contraction of perivascular smooth muscle cells, myofibroblasts and hepatic
stellate cells, which represents about 30% of global intrahepatic resistance and is believed
to be due to the production Defective nitric oxide (NO). The second mechanism, which
maintains and exacerbates HTP, is an increase of splanchnic blood flow caused by increased NO
and other vasodilators at this level
In this regard, we believe that in patients with compensated liver cirrhosis, with portal
pressure gradient> 10 mmHg, both acute responders betablockers test as non-responders, the
association of antifibrotic drugs and / or vasodilators, chronic liver selective May be
beneficial in the control of portal hypertension
Phase:
Phase 4
Details
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau